Oxycodone ER releases a blue dye and nasal irritant when manipulated to help identify illicit users and discourage misuse of the drug. Intellipharma designed the drug as an abuse-deterrent version of Purdue Pharma’s opioid, OcyContin.
The FDA rejected OxyCodone ER in its current form and requested additional proof of the drug’s abuse-deterrent qualities, as well as more information on the drug’s blue dye. An FDA advisory panel in July voted 22-1 against approving the drug, with some experts expressing concerns about the dye’s possible toxicity.
Intellipharma has at least one year to provide the FDA with the requested information. The drugmaker said the regulatory decision will not affect Oxycodone ER’s marketing timeline, according to Reuters.
More articles on opioids:
7 ways clinicians can help reduce opioid misuse and addiction
CVS is now limiting opioid prescriptions
Opioid overdose deaths chip away at US life expectancy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
